Evotec SE (EVO) Total Non-Current Liabilities (2020 - 2026)
Evotec SE's (EVO) quarterly Total Non-Current Liabilities came in at $605063.6 in Q1 2026, down 14.89% year-on-year from $710906.6 in Q1 2025, and down 2.32% quarter-over-quarter from $619465.5 in Q4 2025.
Evotec SE (EVO) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Evotec SE has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $605063.6 for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $605063.6, down 14.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $605063.6 (down 14.89% YoY), and the FY2025 annual result was $619465.5, down 99.91% from the prior year.
- Total Non-Current Liabilities came in at $605063.6 for Q1 2026 at Evotec SE, down from $619465.5 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $747.2 million in Q4 2022 to a low of $404.41 in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $699141.1 (2025), against an average of $177.4 million.
- Across the five-year window, Total Non-Current Liabilities climbed 22.55% in 2022 and plunged 99.91% in 2025, its largest moves.
- Evotec SE's Total Non-Current Liabilities stood at $747.2 million in 2022, then dropped by 3.81% to $718.7 million in 2023, then retreated by 8.5% to $657.6 million in 2024, then slumped by 99.91% to $619465.5 in 2025, then declined by 2.32% to $605063.6 in 2026.
- The last three Total Non-Current Liabilities figures came in at $605063.6 (Q1 2026), $619465.5 (Q4 2025), and $699208.3 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | Evotec SE | 583.10 Mn | 582.58 Mn | - | 605,063.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 605,063.60 |
| Dec 31, 2025 | 619,465.55 |
| Sep 30, 2025 | 699,208.34 |
| Jun 30, 2025 | 655,728.40 |
| Mar 31, 2025 | 710,906.63 |
| Dec 31, 2024 | 657.61 Mn |
| Sep 30, 2024 | 756,366.83 |
| Dec 31, 2023 | 718.71 Mn |
| Dec 31, 2022 | 747.19 Mn |
| Sep 30, 2022 | 699,073.90 |
| Jun 30, 2022 | 404.41 |
| Mar 31, 2022 | 601,058.99 |
| Dec 31, 2021 | 609.69 Mn |
| Sep 30, 2021 | 614,870.98 |
| Dec 31, 2020 | 631.22 Mn |